Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
• Deruxtecan (DXd)-based ADCs have emerged as a highly effective class, particularly for HER2, HER3, and TROP2-positive solid tumors.

Purpose of the Study:

• To review the mechanisms of action, clinical progress, and challenges associated with DXd-based ADCs.
• To highlight the transformative impact of DXd-based ADCs in precision oncology.
• To explore future directions for enhancing the efficacy and accessibility of these therapies.

Main Methods:

• Literature review of preclinical and clinical studies on DXd-based ADCs.
• Analysis of drug mechanisms, including topoisomerase I inhibition and linker technology.
• Evaluation of clinical trial data for approved and investigational DXd-based ADCs.

Main Results:

• DXd-based ADCs demonstrate significant efficacy in breast, lung, gastric, and other solid tumors.
• Trastuzumab deruxtecan and datopotamab deruxtecan are leading examples of successful DXd-based ADCs.
• Key targets include HER2, HER3, and TROP2, with ongoing research expanding their application.

Conclusions:

• DXd-based ADCs offer improved therapeutic indices and have revolutionized precision oncology.
• Despite successes, challenges in toxicity, resistance, and manufacturing require further investigation.
• Future research should focus on optimizing DXd-ADC efficacy, overcoming resistance, and improving manufacturing for broader patient access.